EGFR and non-small cell lung carcinoma: Wen et al. [10] discovered that 73.9% of NSCLC patients in China had at least one targetable gene mutation suggested by the National Comprehensive Cancer Network guidelines, which includes EGFR, ALK, ERBB2, MET, BRAF, RET and ROS1, EGFR mutation accounts for 50.1%.